Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US11590097 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(21 days from now) | |
US11291645 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(21 days from now) | |
US11123321 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(21 days from now) | |
US9376505 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(21 days from now) | |
US7612109 | AM REGENT | Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes |
Feb, 2024
(4 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11478502 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(3 years from now) | |
US11364260 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(3 years from now) | |
US11433091 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(3 years from now) | |
US8895612 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(3 years from now) | |
US7754702 | AM REGENT | Methods and compositions for administration of iron |
Feb, 2028
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication (I) | May 31, 2026 |
New Patient Population (NPP) | Nov 19, 2024 |
New Strength (NS) | Apr 28, 2024 |
Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient
Market Authorisation Date: 25 July, 2013
Treatment: Method to treat ida in adults with intolerance or unsatisfactory response to oral iron & heavy uterine bleeding or gi disorder weighing at least 40 kg by administering iv ferric carboxymaltose to give...
Dosage: SOLUTION;INTRAVENOUS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic